These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24347043)

  • 21. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications.
    Brouillette J; Nattel S
    Can J Cardiol; 2017 Dec; 33(12):1577-1586. PubMed ID: 29173600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sources of drug information: FDA-approved labeling and other official FDA sources.
    Lindstrom JA
    Dermatol Ther; 2009; 22(3):246-56. PubMed ID: 19453349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Black box warnings: what do they mean to pharmacists and patients.
    Martin CM; Borgelt L
    Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of efficacy of heartworm preventive products at the FDA.
    Hampshire VA
    Vet Parasitol; 2005 Oct; 133(2-3):191-5. PubMed ID: 16099105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How much to worry about the FDA warning in the use of citalopram?
    Wang SM; Pae CU
    Expert Rev Neurother; 2013 Aug; 13(8):883-6. PubMed ID: 23965162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of drug-related QT prolongation on FDA regulatory decisions.
    Park E; Willard J; Bi D; Fiszman M; Kozeli D; Koerner J
    Int J Cardiol; 2013 Oct; 168(5):4975-6. PubMed ID: 23920061
    [No Abstract]   [Full Text] [Related]  

  • 31. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
    Weaver J; Grenade LL; Kwon H; Avigan M
    Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: myocardial and infectious adverse reactions as application cases.
    Wang K; Weng Z; Sun L; Sun J; Zhou SF; He L
    Biochem Biophys Res Commun; 2015 Feb; 457(3):249-55. PubMed ID: 25576362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unapproved drugs--the drug information pharmacists' perspective.
    Giouroukakis M; Dryer M
    J Pharm Pract; 2013 Apr; 26(2):112-9. PubMed ID: 23459285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomics: history, barriers, and regulatory solutions.
    Blankstein S
    Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of cardiovascular drugs: the U.S. regulatory milieu from the perspective of a participating nonregulator.
    Borer JS
    J Am Coll Cardiol; 2004 Dec; 44(12):2285-92. PubMed ID: 15607388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of Risk Evaluation and Mitigation Strategy (REMS) programs for managed care pharmacy.
    ; Gandhi G; Chon A; Johnson N; Kidder PA; Lee P; Leung K; Ma I; Ness S; Sampsel E; Schlaifer M; Seifert R; Sternaman DB
    J Manag Care Pharm; 2012 Apr; 18(3):268-75. PubMed ID: 22468736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.